Accéder au contenu
Merck

Peptidylarginine deiminase 2 citrullinates MZB1 and promotes the secretion of IgM and IgA.

Frontiers in immunology (2023-12-14)
Benjamin Geary, Bo Sun, Ronak R Tilvawala, Leonard Barasa, Konstantin Tsoyi, Ivan O Rosas, Paul R Thompson, I-Cheng Ho
RÉSUMÉ

MZB1 is an endoplasmic reticulum residential protein preferentially expressed in plasma cells, marginal zone and B1 B cells. Recent studies on murine B cells show that it interacts with the tail piece of IgM and IgA heavy chain and promotes the secretion of these two classes of immunoglobulin. However, its role in primary human B cells has yet to be determined and how its function is regulated is still unknown. The conversion of peptidylarginine to peptidylcitrulline, also known as citrullination, by peptidylarginine deiminases (PADs) can critically influence the function of proteins in immune cells, such as neutrophils and T cells; however, the role of PADs in B cells remains to be elucidated. An unbiased analysis of human lung citrullinome was conducted to identify citrullinated proteins that are enriched in several chronic lung diseases, including rheumatoid arthritis-associated interstitial lung disease (RA-ILD), chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis, compared to healthy controls. Mass spectrometry, site-specific mutagenesis, and western blotting were used to confirm the citrullination of candidate proteins. Their citrullination was suppressed by pharmacological inhibition or genetic ablation of PAD2 and the impact of their citrullination on the function and differentiation of human B cells was examined with enzyme-linked immunosorbent assay, flow cytometry, and co-immunoprecipitation. Citrullinated MZB1 was preferentially enriched in RA-ILD but not in other chronic lung diseases. MZB1 was a substrate of PAD2 and was citrullinated during the differentiation of human plasmablasts. Ablation or pharmacological inhibition of PAD2 in primary human B cells attenuated the secretion of IgM and IgA but not IgG or the differentiation of IgM or IgA-expressing plasmablasts, recapitulating the effect of ablating MZB1. Furthermore, the physical interaction between endogenous MZB1 and IgM/IgA was attenuated by pharmacological inhibition of PAD2. Our data confirm the function of MZB1 in primary human plasmablasts and suggest that PAD2 promotes IgM/IgA secretion by citrullinating MZB1, thereby contributing to the pathogenesis of rheumatoid arthritis and RA-ILD.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Cocktails d'inhibiteurs de protéases Mini cOmplete, Tablets provided in a glass vial
Sigma-Aldrich
Anti-Human IgM (μ-chain specific) antibody produced in goat, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Anticorps anti-IgG de souris (molécule complète) antibody produced in goat, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Goat Anti-Human IgG Antibody, 2 mg/mL, Chemicon®
Sigma-Aldrich
Anticorps anti-peptidyl-citrulline, clone F95, clone F95, from mouse
Sigma-Aldrich
Anti-Modified Citrulline Antibody, clone C4, clone C4, from human(Recombinant)
Sigma-Aldrich
Anti-MZB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Goat Anti-Human IgG Antibody, biotin conjugate, Chemicon®, from goat
Sigma-Aldrich
Anti-Polyhistidine Tag Antibody, Chemicon®, from mouse